|
Sep 13
|
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
|
|
Sep 13
|
Top fund picks for self-invested pensions
|
|
Sep 12
|
Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug
|
|
Sep 11
|
Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada
|
|
Aug 30
|
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
|
|
Aug 28
|
GSK plc (GSK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 28
|
Five alternatives to Mag 7 stocks if you missed out on Nvidia
|
|
Aug 28
|
GSK shares rise on Delaware Supreme Court appeal in Zantac case
|
|
Jul 31
|
FTSE 100 Live 31 July: HSBC leads index higher, GSK down despite boost to guidance
|
|
Jul 31
|
GSK Lifts Guidance After HIV, Cancer Treatments Boost Sales
|
|
Jul 31
|
Drugs firm GSK raises targets after strong cancer and HIV treatment sales
|
|
Jul 24
|
GSK (GSK) Earnings Expected to Grow: Should You Buy?
|
|
Jun 26
|
Why Is Moderna Stock Trading Lower On Wednesday?
|
|
Jun 26
|
Moderna shares decline, RSV vaccine efficacy lags behind competitors
|
|
Jun 24
|
Britain snubs GSK in favour of US pharma giant for RSV vaccine
|
|
Jun 11
|
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim
|
|
Jun 7
|
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
|
|
Jun 7
|
The City With the highest HIV/AIDS Rates in the US
|
|
Jun 7
|
The total return for GSK (LON:GSK) investors has risen faster than earnings growth over the last year
|
|
Jun 6
|
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
|